ESTRO 2025 - Abstract Book

S2312

Interdisciplinary – Health economics & health services research

ESTRO 2025

Conclusion: In conclusion, these findings suggest that financial well-being among cancer survivors treated with PT does not greatly improve in the first three years following cancer treatment. The concerning implication of these results is that patients who experience financial toxicity during treatment do not recover financially in the following years. The challenge is to identify such patients at an early stage of their treatment journey to allow intervention before detrimental short and long term financial toxicity occurs. The strong correlation between the EORTC-QLQ-C30 financial difficulties item and the FACIT-COST score indicates its potential utility as a screening tool for financial toxicity in clinical settings. References: 1.Bachtiary B, Grawehr L, Grillo Ruggieri F, Held U, Weber DC. Financial Toxicity in Swiss Cancer Patients Treated with Proton Therapy:An Observational Cross-Sectional Study on Self-Reported Outcome.Cancers (Basel).2023;15(23). 2.de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome:The validation of the COmprehensive Score for financial Toxicity (COST).Cancer.2017;123(3):476-84. 3.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology.J Natl Cancer Inst.1993;85(5):365-76. Keywords: financial toxicity, proton therapy, follow-up